Foghorn Therapeutics Inc. develops precision therapeutics for serious diseases by targeting the chromatin regulatory system and correcting abnormal gene expression. The company’s news centers on oncology programs derived from its Gene Traffic Control® platform, including FHD-909, a selective SMARCA2 inhibitor for SMARCA4-mutant cancers, and selective CBP, EP300 and ARID1B degrader programs across ER+ breast cancer, multiple myeloma and other hematologic malignancies.
Recurring updates also cover the company’s collaboration with Lilly, preclinical data presentations, financial results, registered direct financing activity, executive appointments and investor-conference participation.
Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in three upcoming investor conferences. The focus is on its Gene Traffic Control® Platform, which aims to innovate oncology treatments. Key events include:
- Cowen's 3rd Annual Oncology Innovation Summit on June 2 at 10:30 a.m. ET.
- Jefferies Healthcare Conference on June 8 at 1:30 p.m. ET.
- Goldman Sachs 43rd Annual Global Healthcare Conference on June 13 at 3:20 p.m. PT.
Webcasts will be available via the company's website post-event.
Foghorn Therapeutics (Nasdaq: FHTX) announced that the FDA has placed a partial clinical hold on its Phase 1 study of FHD-286 in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), following a report of a death linked to potential differentiation syndrome. While existing patients can continue treatment, new patient enrollment is halted until the issue is resolved. This hold does not affect the ongoing FHD-286 study for metastatic uveal melanoma. The company is suspending guidance on data release timing for the AML/MDS study.
Foghorn Therapeutics (FHTX) continues to advance its pipeline with three phase 1 studies targeting the chromatin regulatory system. Initial clinical data for FHD-286 is anticipated in H2 2022, focusing on cancers such as AML and uveal melanoma, while FHD-609 aims for data in 2023. Recent preclinical findings at AACR highlight FHD-286's anti-tumor activity. The company reported a strong balance sheet with $424.7 million in cash as of March 31, 2022, supporting ongoing development efforts.
Foghorn Therapeutics (FHTX) presented promising preclinical data on its dual inhibitor, FHD-286, at the 2022 AACR Annual Meeting. Targeting the chromatin regulatory system, FHD-286 shows potential in treating cancer, particularly acute myeloid leukemia (AML) and metastatic uveal melanoma. Key findings include significant anti-tumor activity in AML models and favorable combination effects with existing therapies. The data support ongoing Phase 1 trials and underscore FHTX's innovative Gene Traffic Control platform aimed at transforming cancer treatment.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting from April 8-13, 2022, in New Orleans. The company will present preclinical data for FHD-286, a novel BAF inhibitor targeting cancers like acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS), and metastatic uveal melanoma (UM). The oral presentation is set for April 11, showcasing the pharmacological profile and anti-tumor properties of FHD-286. The late-breaking poster on April 13 will address the modulation of SPI1 transcriptional programs related to AML.
Foghorn Therapeutics (Nasdaq: FHTX) will participate in the 2022 Guggenheim Targeted Protein Degradation Day on March 16, 2022, at 9:30 a.m. ET. The event will be held virtually, featuring a fireside chat that highlights Foghorn's innovative work in oncology through its Gene Traffic Control platform. The webcast will be accessible on their website for 90 days following the event. Foghorn focuses on discovering medicines that address genetically determined dependencies in the chromatin regulatory system, with multiple oncology product candidates currently in clinical studies.
Foghorn Therapeutics (FHTX) provided a corporate update highlighting key achievements from 2021 and strategic priorities for 2022. The company reported a significant cash position of $454.3 million following a collaboration with Lilly, which included $380 million in upfront payments. Initial clinical data for its drug candidates, FHD-286 and FHD-609, is expected in the first half of 2022. Foghorn continues to advance its therapeutic pipeline targeting various cancers through its Gene Traffic Control® platform, enhancing its portfolio of oncology treatments.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in Cowen’s 42nd Annual Health Care Conference, scheduled from March 7th to March 9th, 2022. The company will be featured in a panel addressing leukemias and myeloproliferative neoplasms on March 7th at 10:30 a.m. ET. Foghorn is engaged in developing innovative medicines that target genetic dependencies in the chromatin regulatory system, having multiple oncology product candidates, with two in clinical studies. A webcast of the panel will be available for 90 days post-event on their website.
Foghorn Therapeutics (FHTX) announced the promotion of Steven Bellon, Ph.D., to Chief Scientific Officer, effective January 10, 2022. Bellon, a pivotal figure in Foghorn's drug discovery efforts, succeeds Carl Decicco, Ph.D., who is retiring. CEO Adrian Gottschalk praised Decicco's contributions, highlighting the advancement of two clinical programs in 2021. Bellon has been with Foghorn since 2016 and has played a critical role in developing the company's Gene Traffic Control® platform and advancing its diverse therapeutic pipeline, including over 15 programs in oncology.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced its participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will present on January 10, with availability for 90 days. Foghorn focuses on developing novel therapies aimed at genetically determined dependencies within the chromatin regulatory system, particularly in oncology. Its Gene Traffic Control Platform supports the identification of potential drug targets, with multiple candidates currently being investigated in clinical studies.